Akebia Therapeutics (AKBA) Stocktwits Mentions Statistics 2025

1,279 6.8%

1W 100.8% 1M 92.6% 3M 221.4%

Est. daily mentions on Stocktwits.

Similar companies

Company		Stocktwits Mentions
	Amgen AMGN	37 19.4%
	Gilead Sciences GILD	83 15.3%
	Catalyst Pharmaceuticals CPRX	25 37.5%
	Inovio Pharmaceuticals INO	152 22.6%
	Anavex Life Sciences AVXL	323 8%

Month over Month

Est. daily mentions on Stocktwits.

Apr 2025	575	49.5%
Mar 2025	1,139	146.9%
Feb 2025	461	33.6%
Jan 2025	695	51.4%
Dec 2024	459

How often is Akebia Therapeutics mentioned on StockTwits?

Akebia Therapeutics was mentioned an estimated 1,279 times in discussions on StockTwits yesterday.

Analyzing Stocktwits Mentions, how is Akebia Therapeutics performing compared to its industry peers?

Compared to its peers, Akebia Therapeutics ranks in the 44th percentile when it comes to Stocktwits Mentions.

What does a high frequency of StockTwits mentions indicate for Akebia Therapeutics' market sentiment?

A high frequency of mentions on StockTwits for Akebia Therapeutics could indicate strong market interest or sentiment towards the company. It often reflects the trading community's engagement with Akebia Therapeutics' stock, potentially signaling bullish or bearish trends based on the context of the discussions.

How often does AltIndex update information on Akebia Therapeutics' mentions on StockTwits?

AltIndex updates the data on Akebia Therapeutics' mentions on StockTwits daily. This frequent update schedule ensures that investors have access to the most current insights into market sentiment and discussion dynamics related to Akebia Therapeutics' on the platform.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.